

**pembrolizumab 2 mg/kg -
PACLitaxel 80 - CARBOplatin
AUC 1.5 - DOXOrubin 60 -
cyclophosphamide 600**

Regimen: Cycles 1-4 (Part I)

ARIA Protocol Name: Pembro 2mg/kg Pac80 CarbAUC1.5; Pembro 2 mg/kg Doxo60 Cyclo600

Adult Chemotherapy - Medical Oncology

Untreated Triple Negative Breast Cancer Therapy

Name: _____

HCN: _____

Date of Birth: _____



CC4990 0309 04 2023

Allergies:

No Known

Date: DD/MONTH/YYYY
Cycle _____ of _____

Planned Administration Date: DD/MONTH/YYYY

Cycle Duration: 21 days

Date of previous cycle: DD/MONTH/YYYY

MAY PROCEED WITH DOSES AS WRITTEN IF:

- ANC **greater than or equal to** $1.5 \times 10^9/L$ and platelets **greater than or equal to** $90 \times 10^9/L$, otherwise notify Medical Oncologist.
- LFT's and Bilirubin assessed.
- Creatinine clearance assessed.
- Thyroid function assessed.

PREMEDICATIONS (FOR HOSPITAL PHARMACY):

- 45 minutes prior to PACLitaxel: dexamethasone 10 mg IV** in 50 mL normal saline over 15 minutes on days 1, 8 and 15.
- 30 minutes prior to PACLitaxel: diphenhydrAMINE 25 mg IV** in 50 mL normal saline over 15 minutes on days 1, 8 and 15. Administer concurrently with famotidine via y-site.
- 30 minutes prior to PACLitaxel: famotidine 20 mg IV** in 100 mL normal saline over 15 minutes on days 1, 8 and 15. Administer concurrently with diphenhydrAMINE via y-site.
- ondansetron 8 mg PO** on days 1, 8 and 15.
- Other: _____

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Doctor's Order Sheet

**pembrolizumab 2 mg/kg -
PACLitaxel 80 - CARBOplatin
AUC 1.5 - DOXOrubin 60 - cyclophosphamide 600**

Regimen: Cycles 1-4 (Part II)

ARIA Protocol Name: Pembro 2mg/kg Pac80 CarbAUC1.5; Pembro 2 mg/kg Doxo60 Cyclo600

Adult Chemotherapy - Medical Oncology

Untreated Triple Negative Breast Cancer Therapy



CC4990 0309 04 2023

Name: _____

HCN: _____

Date of Birth: _____

Weight: _____ kg Height: _____ cm Body Surface Area (BSA) = _____

CHEMOTHERAPY (FOR HOSPITAL PHARMACY):

pembrolizumab 2 mg/kg X Weight (kg) = _____ **mg (maximum dose 200 mg)**

IV in 50 mL normal saline over 30 minutes on day 1

PACLitaxel 80 mg/m² X BSA = _____ **mg**

Dose modification: **PACLitaxel 80 mg/m²** X BSA - _____ % = _____ **mg**

IV in 100 to 250 mL normal saline PVC Free with 0.2 micron in-line filter over 60 minutes on days 1, 8 and 15

CARBOplatin AUC 1.5 = _____ **mg**

Dose modification: **CARBOplatin AUC 1.5**- _____ % = _____ **mg**

IV in 250 mL normal saline over 30 minutes on days 1, 8 and 15

PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT

Authorized Prescriber: _____ Date: DD/MONTH/YYYY Time: _____

Authorized Prescriber's Signature: _____ ID #: _____

Nurse's Name: _____ Date: DD/MONTH/YYYY Time: _____

Nurse's Signature: _____

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.